BioSpace News Archive

RELIEF THERAPEUTICS Holding SA announced that, on March 22, 2022, it received the certificate of registration for a trademark for RLF-100, from the United States Patent and Trademark Office.

PureTech Health plc, a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced the appointment of Sharon Barber-Lui, MBA, CPA, to its board of directors as a non-executive director and as a member of the Audit Committee.

Oxford Nanopore announces positive evaluation of new method for rapid drug-resistant tuberculosis profiling

Baebies® announced it has received CE Mark for its FINDER® SARS-CoV-2 point-of-care test, which performs RT-PCR testing to detect SARS-CoV-2 on the FINDER 1.5 Instrument.

Orion is planning to change and refocus the strategy of its R&D function. The company would invest in the research and development of new proprietary drugs in two therapy areas, cancer and pain.

NanoTemper’s Dianthus instrument includes breakthrough Spectral Shift technology to handle the most challenging affinity-based screenings in drug discovery.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, reported financial results and business highlights for the fourth quarter and full year 2021.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2021.

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2021.

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2021.